FDA approves generic version of Trilipix

Par receives approval for fenofibric acid delayed-release capsules

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a cholesterol drug made by Par Pharmaceutical Cos., the drug maker said Thursday.

Par announced the approval of generic fenofibric acid delayed-release capsules in the 45-mg and 135-mg strengths. The drug is used to reduce triglycerides and increase "good" high-density lipoprotein cholesterol.

The drug is a generic version of AbbVie's Trilipix, which has sales of about $554 million per year, according to IMS Health.


Login or Register to post a comment.